Mutations in mitogen‐activated protein kinase kinase (MEK) are prevalent in pancreatic ductal adenocarcinoma (PDAC), but many MEK inhibitors inadvertently activate protein kinase B (AKT). This evidence concerns the gene MAP2K7 and pancreatic ductal adenocarcinoma.